Compare TG Therapeutics Inc (TGTX) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Veritone Inc — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Veritone Inc trades at $1.13 (market cap $97.60M). The key difference: TG Therapeutics Inc is far larger — about 84.6× Veritone Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | VERI | |
|---|---|---|
Market Cap | $8.26B | $97.60M |
Sector | Health | Technology |
52-Week High | $59.06 | $8.39 |
52-Week Low | $26.39 | $1.02 |
Enterprise Value | $8.50B | $129.63M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VERI trades at $1.05, up 2.94% today, but remains in a bearish technical trend with negative earnings and cash flow. The company reported a net loss of $111.73M in 2025, with revenue of $92.19M, and faces multiple securities class action lawsuits. Analyst ratings are split evenly between Buy and Hold, with a minority Sell rating, reflecting uncertainty amid financial challenges and legal overhangs.
The outlook is highly speculative due to persistent losses, negative margins, and legal risks. While the low P/S ratio of 0.87 may attract value hunters, the stock carries significant downside risk from operational cash burn and potential settlement costs. Investors should weigh the speculative potential against substantial financial and litigation headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
